(VIANEWS) – The Market ended the session with ERYTECH PHARMA (ERYP.PA) rising 15.36% to €0.89 on Monday while CAC 40 jumped 1.51% to €7,295.55.
ERYTECH PHARMA’s last close was €0.77, 65.86% below its 52-week high of €2.26.
About ERYTECH PHARMA
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ERYTECH PHARMA has a trailing twelve months EPS of €-3.99.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ERYTECH PHARMA’s EBITDA is 7.45.
Yearly Top and Bottom Value
ERYTECH PHARMA’s stock is valued at €0.89 at 21:32 EST, way below its 52-week high of €2.26 and way above its 52-week low of €0.29.
Revenue Growth
Year-on-year quarterly revenue growth declined by 58.5%, now sitting on 2.2M for the twelve trailing months.
More news about ERYTECH PHARMA (ERYP.PA).
